Anti-C5 monoclonal antibody treatment showing pathological resolution of complement-mediated atypical hemolytic uremic syndrome: a case report.

MLA

Kurihara, Shigekazu, et al. “Anti-C5 Monoclonal Antibody Treatment Showing Pathological Resolution of Complement-Mediated Atypical Hemolytic Uremic Syndrome: A Case Report.” BMC Nephrology, vol. 25, no. 1, July 2024, p. 224. EBSCOhost, https://doi.org/10.1186/s12882-024-03662-3.

APA

Kurihara, S., Yamaguchi, A., Sonoda, K., Yamada, Y., Harada, M., Hashimoto, K., Shimojo, H., Ikeda, Y., & Kamijo, Y. (2024). Anti-C5 monoclonal antibody treatment showing pathological resolution of complement-mediated atypical hemolytic uremic syndrome: a case report. BMC Nephrology, 25(1), 224. https://doi.org/10.1186/s12882-024-03662-3

Chicago

Kurihara, Shigekazu, Akinori Yamaguchi, Kosuke Sonoda, Yosuke Yamada, Makoto Harada, Koji Hashimoto, Hisashi Shimojo, Yoichiro Ikeda, and Yuji Kamijo. 2024. “Anti-C5 Monoclonal Antibody Treatment Showing Pathological Resolution of Complement-Mediated Atypical Hemolytic Uremic Syndrome: A Case Report.” BMC Nephrology 25 (1): 224. doi:10.1186/s12882-024-03662-3.